|Articles|September 1, 2003
- Pharmaceutical Executive-09-01-2003
Table of Contents
Table of Contents
Advertisement
Articles in this issue
about 22 years ago
The Outsiderabout 22 years ago
PE's annual Media Spend Trendsabout 22 years ago
A New Deal with Managed Careabout 22 years ago
Matters of (Re)Importabout 22 years ago
Show Us the ValueNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5
